Clinical Trials
10 trialsNCT00436254 2025-04-06
Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer
University of Washington
Phase 1 Completed
NCT02780401 2024-09-19
WOKVAC
University of Washington
Phase 1 Completed
NCT02019524 2020-03-18
J65
San Antonio Military Medical Center
Phase 1 Completed
NCT00079157 2020-02-05
Vaccine Plus Montanide ISA-51 and Sargramostim in Treating Patients With Stage IV Breast Cancer
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT02276300 2019-11-20
HER2
Technical University of Munich
Phase 1 Completed
NCT00003002 2019-02-27
HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer
University of Washington
Phase 1 Completed
NCT00005023 2017-11-30
Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer
University of Washington
Phase 1 Completed
NCT00027807 2016-02-17
Biological Therapy in Treating Women With Stage IV Breast Cancer
Barbara Ann Karmanos Cancer Institute
Phase 1 Completed
NCT00003184 2013-04-04
Vaccine Therapy in Treating Women With Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00028496 2013-01-25
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
National Cancer Institute (NCI)
Phase 1 Completed